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To document the complex “diagnostic odyssey” of patients with mitochondrial disease.
Methods
We analyzed data from 210 Rare Diseases Clinical Research Network Contact Registry
participants who were patients with a biochemical deficiency or self-reported diagnosis of
mitochondrial disease, or their caregivers.
Results
Participants saw an average of 8.19 clinicians (SD 8.0, median 5). The first clinician consulted
about symptoms was typically a primary care physician (56.7%), although 35.2% of participants
initially sought a specialist. Of note, 55.2% of participants received their diagnosis from
a neurologist, 18.2% from a clinical geneticist, and 11.8% from a metabolic disease specialist. A
majority of the participants (54.6%) received 1 or more nonmitochondrial diagnoses before
their final mitochondrial diagnosis. In their pursuit of a diagnosis, 84.8% of participants received
blood tests, 71% amuscle biopsy, 60.5%MRI, and 38.6% urine organic acids. In addition, 39.5%
of the participants underwent mitochondrial DNA sequencing, 19% sequencing of nuclear gene(s),
and 11.4% whole-exome sequencing.
Conclusions
The diagnostic odyssey of patients with mitochondrial disease is complex and burdensome. It
features multiple consultations and tests, and, often, conflicting diagnoses. These reflect disease
variety, diagnostic uncertainty, and clinician unfamiliarity. The current survey provides an
important benchmark. Its replication at appropriate intervals will assist in tracking changes that
may accompany increased popularity of exome testing, more rigorous diagnostic criteria, in-
creased patient reported outcome activity, and trials for promising therapies.
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Mitochondrial diseases comprise a group of rare, about 1 in
4,300, debilitating genetic disorders.1 They are due to defects
affecting the mitochondrial oxidative phosphorylation path-
way and are caused by genetic mutations in the mitochondrial
genome, nuclear DNA, or both.2 The disorders feature a wide
array of multisystemic manifestations that frequently include
developmental abnormalities or regression, myopathy, seiz-
ures, dementia, hearing loss, blindness, strokes, diabetes
mellitus, and premature death affecting both children and
adults. Most mitochondrial diseases are progressive and have
poor prognoses. There are few available treatments.2
Mitochondrial diseases are difficult to diagnose reliably, be-
cause of their wide clinical and genetic heterogeneity, and
require a detailed medical history and extensive knowledge
and expertise on behalf of the diagnosing physician. Anecdotal
evidence from clinicians, researchers, and patients suggests
that before finally receiving a diagnosis of mitochondrial
disease, many patients go through a long ordeal, visiting
numerous clinical specialists, receiving other conflicting di-
agnoses, and enduring repeated and sometimes invasive
testing. In addition, misdiagnoses are not uncommon. The
increasing ubiquity and rapidly falling cost of genetic testing
such as whole-exome sequencing (WES), coupled with
a growing understanding of the genetic origins of mitochon-
drial diseases, are changing how patients receive diagnoses of
mitochondrial diseases. To date, however, research on mito-
chondrial diseases, including recruitment of patients for re-
search studies and clinical trials, has been hampered by their
low incidence, heterogeneity, and underdiagnosis by
clinicians.
The goal of this study was to increase the understanding of




Respondents were enrollees in the established Patient Con-
tact Registry of the Rare Diseases Clinical Research Network
(RDCRN), an initiative of the NIH Office of Rare Disease
Research. The survey was designed and analyzed by inves-
tigators in the North American Mitochondrial Disease
Consortium (NAMDC), an RDCRN member. It was ad-
ministered over 2.5 months between mid-October 2015 and
early January 2016. Institutional review board (IRB) approval
was obtained by the RDCRN Data Management and Co-
ordinating Center at the University of Southern Florida in
Tampa, FL. Eligible individuals were RDCRN Contact
Registry participants with a self-reported diagnosis of mito-
chondrial disease, or their caregivers, who had an email ad-
dress, were able to provide informed consent, and were
capable of completing the survey. Respondents enrolled
online through a link on the NAMDC public website (rar-
ediseasesnetwork.org/namdc).
Data collection
Participation was solicited through an email invitation de-
scribing the purpose and length of the survey, which was sent
to all RDCRN-NAMDC Contact Registry participants with
email addresses. Each email included a unique direct link,
which ensured that the participant’s survey responses could be
linked to basic demographic data they had previously
provided to the RDCRN Registry. Participants entered data
directly online using encrypted communication links. Partic-
ipants were asked to contact the principal investigator (J.G.),
whose contact information was provided in the email, with
questions. A follow-up email with the same content was sent
to eligible participants who had not completed the survey 1
month after data collection began.
The survey (appendix e-1, lww.com/NXG/A41) consisted of
16–25 questions, depending on skip patterns. The estimated
average completion time was 15minutes.Wherever possible, the
survey used questions that required yes or no answers or drop-
down boxes and radio buttons and included an “other” option
permitting a free text answer. Data quality and consistency were
maintained by strict monitoring and constraints at data entry.
Standard protocol approvals, registrations,
and patient consents
Informed consent was obtained and documented online using
an IRB-approved electronic consent form, which confirmed
that participants were free to decline entry into the survey or
to withdraw at any time without prejudice to future treatment.
To avoid linking protected health information to the study
data, participants’ names were not collected; only individuals’
agreements to participate were recorded. IRB approval for the
research was provided by the University of Southern Florida
in Tampa, FL. No personal communications are cited in the
article. The RDCRN study number for the survey is 7,352.
Specific aims
The survey was designed to address 6 prespecified questions:
1. How much time typically elapses between when patients
initially notice symptoms of a mitochondrial disorder and
when they receive the diagnosis of mitochondrial disease?
2. How many physicians do patients typically see before
they receive the diagnosis of mitochondrial disease?
Glossary
IRB = institutional review board; NAMDC = North American Mitochondrial Disease Consortium; PCP = primary care
physician; RDCRN = Rare Diseases Clinical Research Network; WES = whole-exome sequencing.
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3. What testing do patients typically undergo?
4. What other diagnoses, if any, do patients typically
receive?
5. How did receiving a mitochondrial disease diagnosis alter
the patient’s life?
6. If the patient were to learn that their mitochondrial
disease diagnosis was incorrect, what effect would that
have?
We did not collect results of molecular genetic testing because
of inaccuracies in the interpretation of mutations (e.g., single
heterozygous autosomal recessive mutations were sometimes
considered to be the cause of patient’s disease).
Analysis
Results are reported as frequency counts with percentages.
The data were analyzed using IBM SPSS Statistics version 22
(Armonk, NY), and all results were validated independently
using SAS version 9.4.
Results
Two hundred fifteen participants completed the survey. Five
failed to indicate either a clinical diagnosis or a biochemical
deficiency and were excluded, leaving 210 for analysis. Of these,
73 (34.8%) reported both a biochemical deficiency and a clinical
diagnosis; 134 (63.8%) only a clinical diagnosis; and 3 (1.4%)
only a biochemical deficiency. Molecular genetic data were not
specifically collected and were not provided by participants.
Seventy-eight respondents (37.1%) were caretakers, and 132
(62.9%) were patients who took the survey for themselves.
Table 1 presents the breakdown of self-reported mitochon-
drial disease diagnoses. The most common was myopathy
(21.8%), followed by chronic progressive external oph-
thalmoplegia (9.6%), and mitochondrial encephalomyopathy,
lactic acidosis, and stroke-like episodes (9.1%). Fifty-six par-
ticipants (28.4%) reported “Other” mitochondrial diseases.
The diseases entered by these participants were various, and
while some were known mitochondrial diseases not available
in the drop-down list, the majority could be categorized as
biochemical deficiencies, other mitochondrial nuclear gene
defects, or other metabolic diseases with secondary mito-
chondrial dysfunction.
The most commonly reported symptom that motivated
patients to see a doctor was weakness (62.4% of participants),
followed by fatigue (56.2%), difficulty walking (38.6%),
droopy eyelids (32.9%), and impaired coordination (32.4%).
Table 2 provides a complete list. One hundred nineteen
participants (56.7%) reported first discussing their mito-
chondrial disease symptoms with their primary care physician
(PCP), and 74 (35.2%) with a specialist (17 [8.1%] either did
not answer the question or reported first discussing their
mitochondrial disease symptoms with neither a PCP nor
a specialist).
Only 27 respondents (12.9%) reported that the doctor with
whom they first discussed their symptomswas the physicianwho
provided them with a mitochondrial disease diagnosis. Among
the 199 participants who answered the question “Including the
doctor with whom you first discussed your symptoms and the
doctor who diagnosed your mitochondrial disease, how many
doctors did you consult?”, the average number of doctors con-
sulted was 8.19 (SD = 8.0, median = 5) (table 3).
Among patients who reported receiving their mitochondrial
disease diagnosis from a specialist, 112 (55.2%) received their
diagnosis from a neurologist (table 4). The next most com-
mon diagnosing specialists were clinical geneticists (18.2%)
and metabolic disease specialists (11.8%) (table 4).
One hundred seventy-eight participants (84.8%) reported
having blood testing as part of the process of receiving their
mitochondrial disease diagnosis. Among these, 116 reported
tests for blood lactate, 97 for pyruvate, 103 for amino acids,
and 84 reported that their blood was used for genetic testing.
Other common tests were muscle biopsies (71%), MRI
(60.5%), and urine organic acids (38.6%).
Eighty-three participants (39.5%) reported receiving mito-
chondrial DNA sequencing as part of the process of receiving
Table 1 Self-reported mitochondrial disease diagnosis




Leigh syndrome 16 (8.1)




Multiple systemic syndrome 5 (2.5)
NARP 4 (2.0)
MERRF 3 (1.5)





Abbreviations: CPEO= chronic progressive external ophthalmoplegia; LHON=
Leber hereditary optic neuropathy; MELAS = mitochondrial encephalomyop-
athy, lactic acidosis, and stroke-like episodes; MERRF = myoclonic epilepsy
with ragged-red fibers; NARP = neuropathy ataxia retinitis pigmentosa;
SANDO = sensory ataxic neuropathy, dysarthria, and ophthalmoplegia.
a Thirteen participants withmissing or unsatisfactory answers are excluded.
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their mitochondrial disease diagnosis. Forty (19%) reported
undergoing nuclear DNA gene sequencing, and only 24
(11.4%) reported having WES.
One hundred seventy participants (81.7%) reported begin-
ning a treatment management plan after receiving a mito-
chondrial disease diagnosis. One hundred fifty (71.8%)
reported joining a patient support group, patient advocacy
group, or other sort of community for individuals with mi-
tochondrial disease as a result of their diagnosis. Among those
who reported joining a patient community, 84.7% reported
that they felt participation or membership in such a commu-
nity was beneficial for them.
One hundred thirteen participants (54.6%) reported re-
ceiving an alternative nonmitochondrial disease diagnosis
before ultimately receiving their mitochondrial disease
diagnosis; and of these, 31.9% received more than 1. The
most common nonmitochondrial diagnoses are summa-
rized in table 5. The most frequently reported motivating
factor for seeking a different diagnosis after receiving
a nonmitochondrial disease diagnosis was that the treat-
ment the participant was receiving for their disease
symptoms did not help them (reported by 59
participants).





Difficulty walking 81 (38.6)
Other 71 (33.8)
Droopy eyelids 69 (32.9)
Impaired coordination 68 (32.4)
Numbness/weakness in the hands/feet 67 (31.9)
Gastrointestinal discomfort 62 (29.5)
Developmental delay 49 (23.3)
Seizures 39 (18.6)
Loss of vision 31 (14.8)
Hearing loss 27 (12.9)
Diabetes 10 (4.8)
Heart disease 6 (2.9)
Kidney disease 5 (2.4)
Liver disease 3 (1.4)
a Percentages calculated of 210 respondents. Participants could indicate
more than 1 symptom. All indicated at least 1.
Table 3 Number of doctors consulted before diagnosis







a Fourteen participants with missing or unsatisfactory answers are
excluded.
Table 4 Specialty of the diagnosing physician
Specialty Frequency (%)a
Neurology 112 (55.2)
Clinical genetics 37 (18.2)







a Seven participants with missing or unsatisfactory answers are excluded.








Chronic fatigue syndrome 10 (8.8)
Multiple sclerosis 9 (8.0)




Myasthenia gravis 7 (6.2)
Rheumatological 7 (6.2)
Chronic pain 6 (5.3)
a Percentages calculated of 113 participants who received a non-
mitochondrial disease diagnosis.
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Finally, participants were asked: “If you were to learn today
that the mitochondrial disease diagnosis you received is in-
correct, and that you do not in fact have a mitochondrial
disease, how would this affect you?” Among the 201 who
responded to this question, 23 (11.4%) answered that it
would affect them very negatively, 42 (20.9%) negatively, 60
(29.9%) not at all, 45 (22.4%) positively, and 31 (15.4%) very
positively. The number of physicians consulted among the 65
participants who expected negative or very negative feelings
was lower than it was among the 136 participants who did not
expect negative feelings after a mistaken diagnosis (median
6.5 vs 5.0 physicians consulted, p = 0.086 by 2-sidedWilcoxon
rank-sum test, since the number of physicians is not normally
distributed). This 1.5 physician difference is not significant at
the conventional 0.05 level, but is at the exploratory 0.10 level.
We consider this result suggestive, given the relatively small
Ns, and worth further investigation.
Discussion
The results highlight the difficulty, confusion, and burden that
individuals with suspected mitochondrial disease typically
undergo in obtaining a diagnosis. While the survey failed to
capture the amount of time that typically elapses between the
symptom onset and diagnosis, it is clear from several answers
that the process of obtaining a mitochondrial disease di-
agnosis can frequently take many years and multiple doctors
(mean 8.19, median 5). There are multiple reasons for this
diagnostic delay, such as the physician’s unfamiliarity with the
diseases due to their rarity, the heterogeneity of the symptoms
that are difficult to merge into a unifying diagnosis, and the
wide range of initial symptoms that tend to be nonspecific. All
these factors contribute to the high proportion of participants
who received other nonmitochondrial diagnoses (54.3%)
before their final diagnoses.
The variety and sheer amount of testing reported by par-
ticipants is a further reflection of the difficulty of mito-
chondrial disease diagnosis. Of particular note, 71% of
patients reported receiving a muscle biopsy. Until a few
years ago, this painful and invasive procedure was the most
reliable way to obtain a definitive diagnosis through bio-
chemical and histologic testing. Evidence indicates that
clinicians and researchers today are moving away from
biochemical testing and relying more on molecular genetic
testing.3 This is especially true as a rapidly expanding
number of genetic determinants of mitochondrial diseases,
both in mitochondrial and nuclear DNA, are being identi-
fied.2 Planned future surveys will help track changes in
testing practices and will hopefully identify reductions in
invasive testing, such as muscle biopsy, and increased ge-
netic testing, especially whole-exome and whole mito-
chondrial DNA sequencing.4
The survey confirmed considerable anecdotal evidence
from patients and clinicians that individuals with mito-
chondrial disease have often received incorrect diagnoses.
It is perhaps not surprising, given how poorly understood
mitochondrial diseases are, that the most common non-
mitochondrial diagnoses were psychiatric disorders such as
depression and conversion. This further highlights the
unfamiliarity with the diagnosis by health care providers
and the skepticism in recognizing several nonspecific,
seemingly unrelated symptoms as worth investigating.
Manifestations of other reported nonmitochondrial di-
agnoses fit perfectly with common symptoms of mito-
chondrial diseases and were also not surprising. These
include fibromyalgia; Lyme disease; and chronic fatigue
syndrome, which produce manifestations that resemble the
reduced energy state of patients with mitochondrial dis-
ease; MS, which produces neurologic manifestations and
fatigue; and gastrointestinal diseases, which cause cachexia
and reduced gastrointestinal motility that are often present
in patients with mitochondrial disease.5
The effect of a mitochondrial disease diagnosis on participants
proved hard to quantify. Most patients began a treatment
management plan as a result of their diagnosis,6 although
about one-fifth did not. This lack of therapeutic intervention is
largely due to the fact that few disease-modifying treatments
are available.7 In addition, 28.6% of participants did not report
joining a patient support group or community group of any
kind. This is in line with a previous survey showing that the
major support systems for patients include their families and
health care providers.8
Participants were almost evenly divided in their responses to
the question, “If you were to learn today that the mito-
chondrial disease diagnosis you received is incorrect, and
that you do not in fact have a mitochondrial disease, how
would this affect you?” As with the answers regarding
a treatment management plan, this could reflect the lack of
available treatments for mitochondrial diseases. Since a di-
agnosis of mitochondrial disease often does not lead to
a specific treatment, especially one that is likely to control
symptoms and improve quality of life, perhaps participants
ultimately found their diagnosis irrelevant. In a prior mito-
chondrial disease survey,8 patients and families with genet-
ically confirmed and nonconfirmed mitochondrial disease
perceived problems with their medical and social support.
Those with a confirmed genetic diagnosis consistently per-
ceived themselves to be better off than those patients with-
out a confirmed diagnosis, highlighting the emotional stress
and anxiety of having a serious undiagnosed problem and
feeling disadvantaged within the medical community by not
receiving the care they require.
A potential explanation of our provisional finding that par-
ticipants who have seen more physicians may be more likely
to be negatively affected by learning that their diagnosis is
incorrect is that participants who have visited more doctors to
reach their mitochondrial disease diagnosis have spent more
effort searching for answers and are more invested in their
current diagnosis. Learning that this is incorrect and that they
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will have to visit yet another doctor could certainly be very
disheartening.
This survey provided quantitative data confirming the long-
established view of many patients with mitochondrial disease,
researchers, and clinicians that mitochondrial disease di-
agnosis is difficult, confusing, and burdensome. Clinicians and
researchers are making strides to combat this problem, such as
developing clear and widely used diagnostic criteria,2,3,9 and
perfecting genetic testing.4,10 Patients with mitochondrial
disease, through Patient Advocacy Groups or as individuals,
are raising awareness of these diseases. Yet, because of the
rarity and diffuse nature of mitochondrial diseases, the diffi-
culty of diagnosis is not likely to go away any time soon. The
situation may change when genetic testing is more widely
used by health care systems in place now or in the future.
Given these developments, it is important to continue to track
changes in the odyssey of patients with mitochondrial disease;
to advance efforts to reduce the burden on patients; and to
include the links between genetic tests and congruent phe-
notypes in future work.
Strengths and limitations
Strengths of the survey include the attempts to keep the
number of questions to the minimum necessary to achieve the
survey’s aims and to craft clear, concise, closed-ended ques-
tions, all of which to improve data quality.11,12
The primary weakness is the unreliability of self-reported data.
Attempts to minimize this included using closed-ended yes or
no questions; restricting other answers by the use of drop-
down lists; and careful wording to make questions as clear and
unambiguous as possible.
Another issue is that we cannot be certain that participants
actually have the mitochondrial diseases they believe they
have. One strategy to address this was to exclude patients
who did not specifically affirm that they had been informed
by a health professional that they had a mitochondrial
disease or that they had a biochemical deficiency. Fur-
thermore, this problem is somewhat limited. Whether an
individual respondent actually has a mitochondrial disease
is irrelevant with respect to the initial stages of the patient
odyssey. That the respondent initially thinks that they may
have a mitochondrial disease is critical. At the end, we
cannot be sure that the diagnosis is correct. But this is
a problem in the field in general, which we hope the de-
velopment and application of rigorous diagnostic criteria by
NAMDC will alleviate.13 By applying these criteria, which
include clinical, histologic, biochemical, and molecular
genetic data, we will obtain more accurate information
about the diagnostic odyssey of patients with definite mi-
tochondrial diseases.
Further detailed analysis of the data was difficult because of
the many combinations of answers provided by the
respondents For example, 210 participants reported more
than 800 symptoms. Given this, the impact of any individual
symptom on an outcome such as number of physicians seen
cannot be estimated statistically: it is confounded by the many
combinations of other symptoms also displayed by the
patients who present with it.
The survey failed to achieve its aim of determining the typical
amount of time between the symptom onset and diagnosis of
mitochondrial disease. This was an oversight. In retrospect, it
would have been best to simply ask this question of the par-
ticipants outright.
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